Myrna R Nahas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5680766/publications.pdf

Version: 2024-02-01

1040056 839539 33 367 9 18 citations h-index g-index papers 33 33 33 702 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Treatment of Multiple Myeloma With Daratumumab in a Kidney Transplant Patient. American Journal of Therapeutics, 2021, 28, e488-e491.	0.9	3
2	Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. Haematologica, 2021, 106, 1330-1342.	3.5	19
3	Treatment with DC/AML Fusion Vaccine and CD3xCD123 Bi-Specific T-Cell Engager (CD123-CODV-TCE) for Treatment of Acute Myeloid Leukemia. Blood, 2021, 138, 904-904.	1.4	0
4	Prediction of Early Onset Cytokine Release Syndrome and Neurologic Events after Axicabtagene Ciloleucel in Large B-Cell Lymphoma Based on Machine Learning Algorithms. Blood, 2021, 138, 2833-2833.	1.4	0
5	A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL). Blood, 2021, 138, 3543-3543.	1.4	5
6	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e122-e133.	4.6	19
7	Transcriptome Profiling of Immune Response to Dendritic/AML Fusion Vaccine. Biology of Blood and Marrow Transplantation, 2020, 26, S13-S14.	2.0	0
8	Generalized Acquired Cutis Laxa Associated with Monoclonal Gammopathy of Dermatological Significance. Case Reports in Dermatological Medicine, 2020, 2020, 1-10.	0.3	6
9	Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies Biology of Blood and Marrow Transplantation, 2020, 26, S42-S43.	2.0	4
10	Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine. British Journal of Haematology, 2019, 185, 679-690.	2.5	52
11	Hot and Cold: A Concurrent Warm and Cold Autoimmune Hemolytic Anemia in B-cell Prolymphocytic Leukemia. Acta Haematologica, 2019, 141, 222-224.	1.4	2
12	Transfusion Reactions: A Case Study of an Ocular Adverse Event During Autologous Transplantation. Clinical Journal of Oncology Nursing, 2019, 23, 509-513.	0.6	2
13	CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model. Blood, 2019, 134, 1386-1386.	1.4	2
14	Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma. Blood, 2019, 134, 392-392.	1.4	2
15	T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy. Blood, 2019, 134, 2673-2673.	1.4	2
16	Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine. Blood, 2019, 134, 3832-3832.	1.4	0
17	Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies. Blood, 2019, 134, 3227-3227.	1.4	1
18	Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-NaÃ-ve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study. Blood, 2019, 134, 2015-2015.	1.4	3

#	Article	IF	CITATIONS
19	Anti-cancer vaccine therapy for hematologic malignancies: An evolving era. Blood Reviews, 2018, 32, 312-325.	5.7	19
20	Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood, 2018, 131, 2836-2845.	1.4	30
21	Posttransplant Lymphoproliferative Disorder Isolated to the Adrenal Gland in a Liver Transplant Patient. ACG Case Reports Journal, 2018, 5, e10.	0.4	1
22	MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. Journal of Cellular and Molecular Medicine, 2018, 22, 3887-3898.	3.6	12
23	Ex-Vivo Stimulation with DC/AML Fusion Vaccine in the Presence of Cytokines Leads to an Activated T Cell Memory Phenotype and Enhanced Cytotoxicity with Potential for Use As an Adoptive Cellular Therapy. Blood, 2018, 132, 2728-2728.	1.4	1
24	A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model. Blood, 2018, 132, 1446-1446.	1.4	2
25	MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood, 2017, 129, 1791-1801.	1.4	130
26	Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein <scp>MUC</scp> 1. British Journal of Haematology, 2017, 176, 929-938.	2.5	34
27	Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. Molecular Cancer Therapeutics, 2017, 16, 2304-2314.	4.1	10
28	Challenges in vaccine therapy in hematological malignancies and strategies to overcome them. Expert Opinion on Biological Therapy, 2016, 16, 1093-1104.	3.1	3
29	Phase I Clinical Trial Evaluating Abatacept in Patient with Steroid-Refractory Chronic Graft Versus Host Disease. Blood, 2016, 128, 387-387.	1.4	2
30	Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. Blood, 2016, 128, 4175-4175.	1.4	0
31	MUC1-C Inhibition Leads to Decrease in PD-L1 Levels Via up-Regulation of Micro RNAs. Blood, 2016, 128, 2871-2871.	1.4	1
32	Acute Myeloid Leukemia Cells Export c-Myc in Extracellular Vesicles Driving a Proliferation of Immune-Suppressive Myeloid-Derived Suppressor Cells. Blood, 2016, 128, 703-703.	1.4	0
33	A Novel Dendritic Cell-Derived Vaccine in Multiple Myeloma. Blood, 2016, 128, 4484-4484.	1.4	0